Search

Your search keyword '"Jager, Agnes"' showing total 287 results
Start Over Author "Jager, Agnes" Publication Year Range Last 3 years
287 results on '"Jager, Agnes"'

6. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial

Author

Vliek, Sonja, Hilbers, Florentine S., van Werkhoven, Erik, Mandjes, Ingrid, Kessels, Rob, Kleiterp, Sieta, Lips, Esther H., Mulder, Lennart, Kayembe, Mutamba T., Loo, Claudette E., Russell, Nicola S., Vrancken Peeters, Marie-Jeanne T. F. D., Holtkamp, Marjo J., Schot, Margaret, Baars, Joke W., Honkoop, Aafke H., Vulink, Annelie J. E., Imholz, Alex L. T., Vrijaldenhoven, Suzan, van den Berkmortel, Franchette W. P. J., Meerum Terwogt, Jetske M., Schrama, Jolanda G., Kuijer, Philomeen, Kroep, Judith R., van der Padt-Pruijsten, Annemieke, Wesseling, Jelle, Sonke, Gabe S., Gilhuijs, Kenneth G. A., Jager, Agnes, Nederlof, Petra, and Linn, Sabine C.

Published
2023
Full Text
View/download PDF

13. Rare germline copy number variants (CNVs) and breast cancer risk

Author

Dennis, Joe, Tyrer, Jonathan P, Walker, Logan C, Michailidou, Kyriaki, Dorling, Leila, Bolla, Manjeet K, Wang, Qin, Ahearn, Thomas U, Andrulis, Irene L, Anton-Culver, Hoda, Antonenkova, Natalia N, Arndt, Volker, Aronson, Kristan J, Freeman, Laura E Beane, Beckmann, Matthias W, Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bogdanova, Natalia V, Bojesen, Stig E, Brenner, Hermann, Castelao, Jose E, Chang-Claude, Jenny, Chenevix-Trench, Georgia, Clarke, Christine L, Collée, J Margriet, Couch, Fergus J, Cox, Angela, Cross, Simon S, Czene, Kamila, Devilee, Peter, Dörk, Thilo, Dossus, Laure, Eliassen, A Heather, Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A, Figueroa, Jonine, Fletcher, Olivia, Flyger, Henrik, Fritschi, Lin, Gabrielson, Marike, Gago-Dominguez, Manuela, García-Closas, Montserrat, Giles, Graham G, González-Neira, Anna, Guénel, Pascal, Hahnen, Eric, Haiman, Christopher A, Hall, Per, Hollestelle, Antoinette, Hoppe, Reiner, Hopper, John L, Howell, Anthony, Jager, Agnes, Jakubowska, Anna, John, Esther M, Johnson, Nichola, Jones, Michael E, Jung, Audrey, Kaaks, Rudolf, Keeman, Renske, Khusnutdinova, Elza, Kitahara, Cari M, Ko, Yon-Dschun, Kosma, Veli-Matti, Koutros, Stella, Kraft, Peter, Kristensen, Vessela N, Kubelka-Sabit, Katerina, Kurian, Allison W, Lacey, James V, Lambrechts, Diether, Larson, Nicole L, Linet, Martha, Ogrodniczak, Alicja, Mannermaa, Arto, Manoukian, Siranoush, Margolin, Sara, Mavroudis, Dimitrios, Milne, Roger L, Muranen, Taru A, Murphy, Rachel A, Nevanlinna, Heli, Olson, Janet E, Olsson, Håkan, Park-Simon, Tjoung-Won, Perou, Charles M, Peterlongo, Paolo, Plaseska-Karanfilska, Dijana, Pylkäs, Katri, Rennert, Gad, Saloustros, Emmanouil, Sandler, Dale P, Sawyer, Elinor J, Schmidt, Marjanka K, Schmutzler, Rita K, Shibli, Rana, Smeets, Ann, and Soucy, Penny

Subjects
Human Genome, Breast Cancer, Genetics, Clinical Research, Cancer, Prevention, 2.1 Biological and endogenous factors, Aetiology, Breast Neoplasms, Case-Control Studies, DNA Copy Number Variations, Female, Genome, Human, Genome-Wide Association Study, Germ Cells, Humans, Risk Factors, NBCS Collaborators, CTS Consortium, ABCTB Investigators, kConFab/AOCS Investigators
Abstract

Germline copy number variants (CNVs) are pervasive in the human genome but potential disease associations with rare CNVs have not been comprehensively assessed in large datasets. We analysed rare CNVs in genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data. Gene burden tests detected the strongest association for deletions in BRCA1 (P = 3.7E-18). Nine other genes were associated with a p-value

Published
2022

14. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women

Author

Figlioli, Gisella, Billaud, Amandine, Ahearn, Thomas U., Antonenkova, Natalia N., Becher, Heiko, Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blok, Marinus J., Bogdanova, Natalia V., Bonanni, Bernardo, Burwinkel, Barbara, Camp, Nicola J., Campbell, Archie, Castelao, Jose E., Cessna, Melissa H., Chanock, Stephen J., Czene, Kamila, Devilee, Peter, Dörk, Thilo, Engel, Christoph, Eriksson, Mikael, Fasching, Peter A., Figueroa, Jonine D., Gabrielson, Marike, Gago-Dominguez, Manuela, García-Closas, Montserrat, González-Neira, Anna, Grassmann, Felix, Guénel, Pascal, Gündert, Melanie, Hadjisavvas, Andreas, Hahnen, Eric, Hall, Per, Hamann, Ute, Harrington, Patricia A., He, Wei, Hillemanns, Peter, Hollestelle, Antoinette, Hooning, Maartje J., Hoppe, Reiner, Howell, Anthony, Humphreys, Keith, Jager, Agnes, Jakubowska, Anna, Khusnutdinova, Elza K., Ko, Yon-Dschun, Kristensen, Vessela N., Lindblom, Annika, Lissowska, Jolanta, Lubiński, Jan, Mannermaa, Arto, Manoukian, Siranoush, Margolin, Sara, Mavroudis, Dimitrios, Newman, William G., Obi, Nadia, Panayiotidis, Mihalis I., Rashid, Muhammad U., Rhenius, Valerie, Rookus, Matti A., Saloustros, Emmanouil, Sawyer, Elinor J., Schmutzler, Rita K., Shah, Mitul, Sironen, Reijo, Southey, Melissa C., Suvanto, Maija, Tollenaar, Rob A. E. M., Tomlinson, Ian, Truong, Thérèse, van der Kolk, Lizet E., van Veen, Elke M., Wappenschmidt, Barbara, Yang, Xiaohong R., Bolla, Manjeet K., Dennis, Joe, Dunning, Alison M., Easton, Douglas F., Lush, Michael, Michailidou, Kyriaki, Pharoah, Paul D. P., Wang, Qin, Adank, Muriel A., Schmidt, Marjanka K., Andrulis, Irene L., Chang-Claude, Jenny, Nevanlinna, Heli, Chenevix-Trench, Georgia, Evans, D. Gareth, Milne, Roger L., Radice, Paolo, and Peterlongo, Paolo

Published
2023
Full Text
View/download PDF

15. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial

Author

Voorwerk, Leonie, Isaeva, Olga I., Horlings, Hugo M., Balduzzi, Sara, Chelushkin, Maksim, Bakker, Noor A. M., Champanhet, Elisa, Garner, Hannah, Sikorska, Karolina, Loo, Claudette E., Kemper, Inge, Mandjes, Ingrid A. M., de Maaker, Michiel, van Geel, Jasper J. L., Boers, Jorianne, de Boer, Maaike, Salgado, Roberto, van Dongen, Marloes G. J., Sonke, Gabe S., de Visser, Karin E., Schumacher, Ton N., Blank, Christian U., Wessels, Lodewyk F. A., Jager, Agnes, Tjan-Heijnen, Vivianne C. G., Schröder, Carolien P., Linn, Sabine C., and Kok, Marleen

Published
2023
Full Text
View/download PDF

18. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

Author

Morra, Anna, Escala-Garcia, Maria, Beesley, Jonathan, Keeman, Renske, Canisius, Sander, Ahearn, Thomas U, Andrulis, Irene L, Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L, Augustinsson, Annelie, Beane Freeman, Laura E, Becher, Heiko, Beckmann, Matthias W, Behrens, Sabine, Bojesen, Stig E, Bolla, Manjeet K, Brenner, Hermann, Brüning, Thomas, Buys, Saundra S, Caan, Bette, Campa, Daniele, Canzian, Federico, Castelao, Jose E, Chang-Claude, Jenny, Chanock, Stephen J, Cheng, Ting-Yuan David, Clarke, Christine L, Colonna, Sarah V, Couch, Fergus J, Cox, Angela, Cross, Simon S, Czene, Kamila, Daly, Mary B, Dennis, Joe, Dörk, Thilo, Dossus, Laure, Dunning, Alison M, Dwek, Miriam, Eccles, Diana M, Ekici, Arif B, Eliassen, A Heather, Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A, Flyger, Henrik, Fritschi, Lin, Gago-Dominguez, Manuela, García-Sáenz, José A, Giles, Graham G, Grip, Mervi, Guénel, Pascal, Gündert, Melanie, Hahnen, Eric, Haiman, Christopher A, Håkansson, Niclas, Hall, Per, Hamann, Ute, Hart, Steven N, Hartikainen, Jaana M, Hartmann, Arndt, He, Wei, Hooning, Maartje J, Hoppe, Reiner, Hopper, John L, Howell, Anthony, Hunter, David J, Jager, Agnes, Jakubowska, Anna, Janni, Wolfgang, John, Esther M, Jung, Audrey Y, Kaaks, Rudolf, Keupers, Machteld, Kitahara, Cari M, Koutros, Stella, Kraft, Peter, Kristensen, Vessela N, Kurian, Allison W, Lacey, James V, Lambrechts, Diether, Le Marchand, Loic, Lindblom, Annika, Linet, Martha, Luben, Robert N, Lubiński, Jan, Lush, Michael, Mannermaa, Arto, Manoochehri, Mehdi, Margolin, Sara, Martens, John WM, Martinez, Maria Elena, Mavroudis, Dimitrios, Michailidou, Kyriaki, Milne, Roger L, Mulligan, Anna Marie, Muranen, Taru A, Nevanlinna, Heli, Newman, William G, and Nielsen, Sune F

Subjects
Clinical Research, Cancer, Breast Cancer, Human Genome, Genetics, 2.1 Biological and endogenous factors, Aetiology, Breast Neoplasms, Female, Genome-Wide Association Study, Germ-Line Mutation, Humans, Polymorphism, Single Nucleotide, Prognosis, Survival Analysis, Common germline genetic variants, Breast cancer-specific survival, Patient subgroups, Tumor biology, Systemic treatment, NBCS Collaborators, ABCTB Investigators, kConFab Investigators, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundGiven the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breast cancer patients.MethodsWe performed genome-wide association analyses within 15 subgroups of breast cancer patients based on prognostic factors, including hormone receptors, tumor grade, age, and type of systemic treatment. Analyses were based on 91,686 female patients of European ancestry from the Breast Cancer Association Consortium, including 7531 breast cancer-specific deaths over a median follow-up of 8.1 years. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. We assessed the probability of these associations being true positives via the Bayesian false discovery probability (BFDP

Published
2021

19. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

Author

Park, Hanla A, Neumeyer, Sonja, Michailidou, Kyriaki, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Ahearn, Thomas U, Andrulis, Irene L, Anton-Culver, Hoda, Antonenkova, Natalia N, Arndt, Volker, Aronson, Kristan J, Augustinsson, Annelie, Baten, Adinda, Beane Freeman, Laura E, Becher, Heiko, Beckmann, Matthias W, Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bogdanova, Natalia V, Bojesen, Stig E, Brauch, Hiltrud, Brenner, Hermann, Brucker, Sara Y, Burwinkel, Barbara, Campa, Daniele, Canzian, Federico, Castelao, Jose E, Chanock, Stephen J, Chenevix-Trench, Georgia, Clarke, Christine L, Conroy, Don M, Couch, Fergus J, Cox, Angela, Cross, Simon S, Czene, Kamila, Daly, Mary B, Devilee, Peter, Dörk, Thilo, dos-Santos-Silva, Isabel, Dwek, Miriam, Eccles, Diana M, Eliassen, A Heather, Engel, Christoph, Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A, Flyger, Henrik, Fritschi, Lin, García-Closas, Montserrat, García-Sáenz, José A, Gaudet, Mia M, Giles, Graham G, Glendon, Gord, Goldberg, Mark S, Goldgar, David E, González-Neira, Anna, Grip, Mervi, Guénel, Pascal, Hahnen, Eric, Haiman, Christopher A, Håkansson, Niclas, Hall, Per, Hamann, Ute, Han, Sileny, Harkness, Elaine F, Hart, Steven N, He, Wei, Heemskerk-Gerritsen, Bernadette AM, Hopper, John L, Hunter, David J, Jager, Agnes, Jakubowska, Anna, John, Esther M, Jung, Audrey, Kaaks, Rudolf, Kapoor, Pooja Middha, Keeman, Renske, Khusnutdinova, Elza, Kitahara, Cari M, Koppert, Linetta B, Koutros, Stella, Kristensen, Vessela N, Kurian, Allison W, Lacey, James, Lambrechts, Diether, Le Marchand, Loic, Lo, Wing-Yee, Lubiński, Jan, Mannermaa, Arto, Manoochehri, Mehdi, Margolin, Sara, Martinez, Maria Elena, Mavroudis, Dimitrios, Meindl, Alfons, Menon, Usha, Milne, Roger L, Muranen, Taru A, and Nevanlinna, Heli

Subjects
Genetics, Cancer, Substance Misuse, Clinical Research, Human Genome, Prevention, Drug Abuse (NIDA only), Breast Cancer, Tobacco, Tobacco Smoke and Health, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Breast Neoplasms, Case-Control Studies, Cigarette Smoking, Female, Genetic Pleiotropy, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotyping Techniques, Humans, Mendelian Randomization Analysis, Polymorphism, Single Nucleotide, NBCS Collaborators, ABCTB Investigators, kConFab Investigators, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundDespite a modest association between tobacco smoking and breast cancer risk reported by recent epidemiological studies, it is still equivocal whether smoking is causally related to breast cancer risk.MethodsWe applied Mendelian randomisation (MR) to evaluate a potential causal effect of cigarette smoking on breast cancer risk. Both individual-level data as well as summary statistics for 164 single-nucleotide polymorphisms (SNPs) reported in genome-wide association studies of lifetime smoking index (LSI) or cigarette per day (CPD) were used to obtain MR effect estimates. Data from 108,420 invasive breast cancer cases and 87,681 controls were used for the LSI analysis and for the CPD analysis conducted among ever-smokers from 26,147 cancer cases and 26,072 controls. Sensitivity analyses were conducted to address pleiotropy.ResultsGenetically predicted LSI was associated with increased breast cancer risk (OR 1.18 per SD, 95% CI: 1.07-1.30, P = 0.11 × 10-2), but there was no evidence of association for genetically predicted CPD (OR 1.02, 95% CI: 0.78-1.19, P = 0.85). The sensitivity analyses yielded similar results and showed no strong evidence of pleiotropic effect.ConclusionOur MR study provides supportive evidence for a potential causal association with breast cancer risk for lifetime smoking exposure but not cigarettes per day among smokers.

Published
2021

20. Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study

Author

Eijkelboom, Anouk H., de Munck, Linda, Menke-van der Houven van Oordt, C. Willemien, Broeders, Mireille J. M., van den Bongard, Desiree H. J. G., Strobbe, Luc J. A., Mureau, Marc A. M., Lobbes, Marc B. I., Westenend, Pieter J., Koppert, Linetta B., Jager, Agnes, Siemerink, Ester J. M., Wesseling, Jelle, Verkooijen, Helena M., Vrancken Peeters, Marie-Jeanne T. F. D., Smidt, Marjolein L., Tjan-Heijnen, Vivianne C. G., and Siesling, Sabine

Published
2023
Full Text
View/download PDF

24. Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study

Author

van Barele, Mark, Rieborn, Amy, Heemskerk-Gerritsen, Bernadette A. M., Obdeijn, Inge-Marie, Koppert, Linetta B., Loo, Claudette E., Tollenaar, Rob A. E. M., Ausems, Margreet G. E. M., van de Beek, Irma, Berger, Lieke P. V., de Boer, Maaike, van Hest, Liselot P., Kets, C. Marleen, Rookus, Matti, Schmidt, Marjanka K., Jager, Agnes, and Hooning, Maartje J.

Published
2022
Full Text
View/download PDF

25. Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial.

Author

Luijendijk, Maryse, primary, Lee Meeuw Kjoe, Philippe, additional, Wortelboer, Noor, additional, Van Ommen - Nijhof, Annemiek, additional, Agelink van Rentergem, Joost, additional, Vermeulen, Ivar, additional, Konings, Inge, additional, Jager, Agnes, additional, Sonke, Gabe S., additional, Van Der Wall, Elsken, additional, and Schagen, Sanne B., additional

Published
2024
Full Text
View/download PDF

26. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

Author

Meijer, Titia G., Nguyen, Luan, Van Hoeck, Arne, Sieuwerts, Anieta M., Verkaik, Nicole S., Ladan, Marjolijn M., Ruigrok-Ritstier, Kirsten, van Deurzen, Carolien H. M., van de Werken, Harmen J. G., Lips, Esther H., Linn, Sabine C., Memari, Yasin, Davies, Helen, Nik-Zainal, Serena, Kanaar, Roland, Martens, John W. M., Cuppen, Edwin, Jager, Agnes, and van Gent, Dik C.

Published
2022
Full Text
View/download PDF

27. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer

Author

Braal, C. Louwrens, Jager, Agnes, Hoop, Esther Oomen-de, Westenberg, Justin D., Lommen, Koen M. W. T., de Bruijn, Peter, Vastbinder, Mijntje B., van Rossum-Schornagel, Quirine C., Thijs-Visser, Martine F., van Alphen, Robbert J., Struik, Liesbeth E. M., Zuetenhorst, Hanneke J. M., Mathijssen, Ron H. J., and Koolen, Stijn L. W.

Published
2022
Full Text
View/download PDF

32. Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer

Author

Boers, Jorianne, primary, Eisses, Bertha, additional, Zwager, Mieke, additional, van Geel, Jasper, additional, Bensch, Frederike, additional, de Vries, Erik, additional, Hospers, Geke, additional, Glaudemans, Andor, additional, Brouwers, Adrienne, additional, den Dekker, Martijn, additional, Elias, Sjoerd, additional, Kuip, Evelien, additional, van Herpen, Carla, additional, Jager, Agnes, additional, van der Veldt, Astrid, additional, Oprea-Lager, Daniela, additional, de Vries, Elisabeth, additional, van der Vegt, Bert, additional, Menke-van der Houven van Oordt, Willemien, additional, and Schröder, Carolina, additional

Published
2024
Full Text
View/download PDF

33. Figure S6 from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, primary, Cuypere, Eveline, primary, Dalenc, Florence, primary, Dirix, Luc, primary, Chan, Steve, primary, Marme, Frederik, primary, Schröder, Carolina P., primary, Huober, Jens, primary, Duhoux, Francois P., primary, Vuylsteke, Peter, primary, Jager, Agnes, primary, Brain, Etienne, primary, Kuemmel, Sherko, primary, Pápai, Zsuzsanna, primary, Menke-van der Houven van Oordt, Catharina Willemien, primary, Perjesi, Luca, primary, Mueller, Christian, primary, Brignone, Chrystelle, primary, and Triebel, Frederic, primary

Published
2024
Full Text
View/download PDF

34. Supplementary Data 1 from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, primary, Cuypere, Eveline, primary, Dalenc, Florence, primary, Dirix, Luc, primary, Chan, Steve, primary, Marme, Frederik, primary, Schröder, Carolina P., primary, Huober, Jens, primary, Duhoux, Francois P., primary, Vuylsteke, Peter, primary, Jager, Agnes, primary, Brain, Etienne, primary, Kuemmel, Sherko, primary, Pápai, Zsuzsanna, primary, Menke-van der Houven van Oordt, Catharina Willemien, primary, Perjesi, Luca, primary, Mueller, Christian, primary, Brignone, Chrystelle, primary, and Triebel, Frederic, primary

Published
2024
Full Text
View/download PDF

35. Data from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, primary, Cuypere, Eveline, primary, Dalenc, Florence, primary, Dirix, Luc, primary, Chan, Steve, primary, Marme, Frederik, primary, Schröder, Carolina P., primary, Huober, Jens, primary, Duhoux, Francois P., primary, Vuylsteke, Peter, primary, Jager, Agnes, primary, Brain, Etienne, primary, Kuemmel, Sherko, primary, Pápai, Zsuzsanna, primary, Menke-van der Houven van Oordt, Catharina Willemien, primary, Perjesi, Luca, primary, Mueller, Christian, primary, Brignone, Chrystelle, primary, and Triebel, Frederic, primary

Published
2024
Full Text
View/download PDF

36. Detection of Drug-induced Interstitial Lung Disease Caused by Cancer Treatment Using Electronic Nose Exhaled Breath Analysis.

Author

van der Sar, Iris G., Wijsenbeek, Marlies S., Dumoulin, Daphne W., Jager, Agnes, van der Veldt, Astrid A. M., Rossius, Mariska J. P., Dingemans, Anne-Marie C., and Moor, Catharina C.

Subjects
INTERSTITIAL lung diseases, LUNGS, ELECTRONIC noses, DRUG side effects, CANCER treatment, ETIOLOGY of cancer
Abstract

The article examines the rising concern of Drug-induced Interstitial Lung Disease (DIILD) in cancer treatments, emphasizing the urgent need for a noninvasive diagnostic tool. Topics discussed include DIILD incidence rates, challenges in diagnosis, and the potential of electronic nose technology to differentiate patients with DIILD from those without.

Published
2024
Full Text
View/download PDF

37. Continuity of care for patients with de novo metastatic cancer during the COVID‐19 pandemic: A population‐based observational study.

Author

Slotman, Ellis, Weijzen, Feike, Fransen, Heidi P., van Hoeve, Jolanda C., Huijben, Auke M. T., Kuip, Evelien J. M., Jager, Agnes, Kunst, Peter W. A., van Laarhoven, Hanneke W. M., Tol, Jolien, Tjan‐Heijnen, Vivianne C. G., Raijmakers, Natasja J. H., van der Linden, Yvette M., and Siesling, Sabine

Subjects
COVID-19 pandemic, CONTINUUM of care, METASTASIS, COVID-19 treatment, CANCER treatment
Abstract

During the COVID‐19 pandemic recommendations were made to adapt cancer care. This population‐based study aimed to investigate possible differences between the treatment of patients with metastatic cancer before and during the pandemic by comparing the initial treatments in five COVID‐19 periods (weeks 1–12 2020: pre‐COVID‐19, weeks 12–20 2020: 1st peak, weeks 21–41 2020: recovery, weeks 42–53 2020: 2nd peak, weeks 1–20 2021: prolonged 2nd peak) with reference data from 2017 to 2019. The proportion of patients receiving different treatment modalities (chemotherapy, hormonal therapy, immunotherapy or targeted therapy, radiotherapy primary tumor, resection primary tumor, resection metastases) within 6 weeks of diagnosis and the time between diagnosis and first treatment were compared by period. In total, 74,208 patients were included. Overall, patients were more likely to receive treatments in the COVID‐19 periods than in previous years. This mainly holds for hormone therapy, immunotherapy or targeted therapy and resection of metastases. Lower odds were observed for resection of the primary tumor during the recovery period (OR 0.87; 95% CI 0.77–0.99) and for radiotherapy on the primary tumor during the prolonged 2nd peak (OR 0.84; 95% CI 0.72–0.98). The time from diagnosis to the start of first treatment was shorter, mainly during the 1st peak (average 5 days, p <.001). These findings show that during the first 1.5 years of the COVID‐19 pandemic, there were only minor changes in the initial treatment of metastatic cancer. Remarkably, time from diagnosis to first treatment was shorter. Overall, the results suggest continuity of care for patients with metastatic cancer during the pandemic. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Reduction in potentially inappropriate end-of-life hospital care for cancer patients during the COVID-19 pandemic: A retrospective population-based study

Author

Slotman, Ellis, primary, Fransen, Heidi P, additional, van Laarhoven, Hanneke WM, additional, van den Beuken-van Everdingen, Marieke HJ, additional, Tjan-Heijnen, Vivianne CG, additional, Huijben, Auke MT, additional, Jager, Agnes, additional, van Zuylen, Lia, additional, Kuip, Evelien JM, additional, van der Linden, Yvette M, additional, Raijmakers, Natasja JH, additional, and Siesling, Sabine, additional

Published
2023
Full Text
View/download PDF

39. The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study

Author

Öztekin, Selin, primary, Hooning, Maartje J., additional, van Deurzen, Carolien H. M., additional, Dietvorst, Anne‐Marie H. P., additional, Drooger, Jan C., additional, Kitzen, Jos J. E. M., additional, Martens, John W. M., additional, van der Padt‐Pruijsten, Annemieke, additional, Vastbinder, Mijntje B., additional, Zuetenhorst, Hanneke, additional, Heemskerk‐Gerritsen, Bernadette A. M., additional, and Jager, Agnes, additional

Published
2023
Full Text
View/download PDF

40. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, additional, Cuypere, Eveline, additional, Dalenc, Florence, additional, Dirix, Luc, additional, Chan, Steve, additional, Marme, Frederik, additional, Schröder, Carolina P., additional, Huober, Jens, additional, Duhoux, Francois P., additional, Vuylsteke, Peter, additional, Jager, Agnes, additional, Brain, Etienne, additional, Kuemmel, Sherko, additional, Pápai, Zsuzsanna, additional, Menke-van der Houven van Oordt, Catharina Willemien, additional, Perjesi, Luca, additional, Mueller, Christian, additional, Brignone, Chrystelle, additional, and Triebel, Frederic, additional

Published
2023
Full Text
View/download PDF

41. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Author

Coignard, Juliette, Lush, Michael, Beesley, Jonathan, O’Mara, Tracy A., Dennis, Joe, Tyrer, Jonathan P., Barnes, Daniel R., McGuffog, Lesley, Leslie, Goska, Bolla, Manjeet K., Adank, Muriel A., Agata, Simona, Ahearn, Thomas, Aittomäki, Kristiina, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Arnold, Norbert, Aronson, Kristan J., Arun, Banu K., Augustinsson, Annelie, Azzollini, Jacopo, Barrowdale, Daniel, Baynes, Caroline, Becher, Heiko, Bermisheva, Marina, Bernstein, Leslie, Białkowska, Katarzyna, Blomqvist, Carl, Bojesen, Stig E., Bonanni, Bernardo, Borg, Ake, Brauch, Hiltrud, Brenner, Hermann, Burwinkel, Barbara, Buys, Saundra S., Caldés, Trinidad, Caligo, Maria A., Campa, Daniele, Carter, Brian D., Castelao, Jose E., Chang-Claude, Jenny, Chanock, Stephen J., Chung, Wendy K., Claes, Kathleen B. M., Clarke, Christine L., Collée, J. Margriet, Conroy, Don M., Czene, Kamila, Daly, Mary B., Devilee, Peter, Diez, Orland, Ding, Yuan Chun, Domchek, Susan M., Dörk, Thilo, dos-Santos-Silva, Isabel, Dunning, Alison M., Dwek, Miriam, Eccles, Diana M., Eliassen, A. Heather, Engel, Christoph, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Flyger, Henrik, Fostira, Florentia, Friedman, Eitan, Fritschi, Lin, Frost, Debra, Gago-Dominguez, Manuela, Gapstur, Susan M., Garber, Judy, Garcia-Barberan, Vanesa, García-Closas, Montserrat, García-Sáenz, José A., Gaudet, Mia M., Gayther, Simon A., Gehrig, Andrea, Georgoulias, Vassilios, Giles, Graham G., Godwin, Andrew K., Goldberg, Mark S., Goldgar, David E., González-Neira, Anna, Greene, Mark H., Guénel, Pascal, Haeberle, Lothar, Hahnen, Eric, Haiman, Christopher A., Håkansson, Niclas, Hall, Per, Hamann, Ute, Harrington, Patricia A., Hart, Steven N., He, Wei, Hogervorst, Frans B. L., Hollestelle, Antoinette, Hopper, John L., Horcasitas, Darling J., Hulick, Peter J., Hunter, David J., Imyanitov, Evgeny N., Jager, Agnes, Jakubowska, Anna, James, Paul A., Jensen, Uffe Birk, John, Esther M., Jones, Michael E., Kaaks, Rudolf, Kapoor, Pooja Middha, Karlan, Beth Y., Keeman, Renske, Khusnutdinova, Elza, Kiiski, Johanna I., Ko, Yon-Dschun, Kosma, Veli-Matti, Kraft, Peter, Kurian, Allison W., Laitman, Yael, Lambrechts, Diether, Le Marchand, Loic, Lester, Jenny, Lesueur, Fabienne, Lindstrom, Tricia, Lopez-Fernández, Adria, Loud, Jennifer T., Luccarini, Craig, Mannermaa, Arto, Manoukian, Siranoush, Margolin, Sara, Martens, John W. M., Mebirouk, Noura, Meindl, Alfons, Miller, Austin, Milne, Roger L., Montagna, Marco, Nathanson, Katherine L., Neuhausen, Susan L., Nevanlinna, Heli, Nielsen, Finn C., O’Brien, Katie M., Olopade, Olufunmilayo I., Olson, Janet E., Olsson, Håkan, Osorio, Ana, Ottini, Laura, Park-Simon, Tjoung-Won, Parsons, Michael T., Pedersen, Inge Sokilde, Peshkin, Beth, Peterlongo, Paolo, Peto, Julian, Pharoah, Paul D. P., Phillips, Kelly-Anne, Polley, Eric C., Poppe, Bruce, Presneau, Nadege, Pujana, Miquel Angel, Punie, Kevin, Radice, Paolo, Rantala, Johanna, Rashid, Muhammad U., Rennert, Gad, Rennert, Hedy S., Robson, Mark, Romero, Atocha, Rossing, Maria, Saloustros, Emmanouil, Sandler, Dale P., Santella, Regina, Scheuner, Maren T., Schmidt, Marjanka K., Schmidt, Gunnar, Scott, Christopher, Sharma, Priyanka, Soucy, Penny, Southey, Melissa C., Spinelli, John J., Steinsnyder, Zoe, Stone, Jennifer, Stoppa-Lyonnet, Dominique, Swerdlow, Anthony, Tamimi, Rulla M., Tapper, William J., Taylor, Jack A., Terry, Mary Beth, Teulé, Alex, Thull, Darcy L., Tischkowitz, Marc, Toland, Amanda E., Torres, Diana, Trainer, Alison H., Truong, Thérèse, Tung, Nadine, Vachon, Celine M., Vega, Ana, Vijai, Joseph, Wang, Qin, Wappenschmidt, Barbara, Weinberg, Clarice R., Weitzel, Jeffrey N., Wendt, Camilla, Wolk, Alicja, Yadav, Siddhartha, Yang, Xiaohong R., Yannoukakos, Drakoulis, Zheng, Wei, Ziogas, Argyrios, Zorn, Kristin K., Park, Sue K., Thomassen, Mads, Offit, Kenneth, Schmutzler, Rita K., Couch, Fergus J., Simard, Jacques, Chenevix-Trench, Georgia, Easton, Douglas F., Andrieu, Nadine, and Antoniou, Antonis C.

Published
2021
Full Text
View/download PDF

42. The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.

Author

Öztekin, Selin, Hooning, Maartje J., van Deurzen, Carolien H. M., Dietvorst, Anne‐Marie H. P., Drooger, Jan C., Kitzen, Jos J. E. M., Martens, John W. M., van der Padt‐Pruijsten, Annemieke, Vastbinder, Mijntje B., Zuetenhorst, Hanneke, Heemskerk‐Gerritsen, Bernadette A. M., and Jager, Agnes

Subjects
LOBULAR carcinoma, HORMONE receptor positive breast cancer, ADJUVANT chemotherapy, HORMONE therapy, EPIDERMAL growth factor receptors, SURVIVAL rate, OVERALL survival
Abstract

Background: Despite histological and molecular differences between invasive lobular carcinoma (ILC) and invasive carcinoma of no special type, according to national treatment guidelines no distinction is made regarding the use of (neo)adjuvant chemotherapy. Studies on the long‐term outcome of chemotherapy in patients with ILC are scarce and show inconclusive results. Methods: All patients with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative ILC with an indication for chemotherapy treated with adjuvant endocrine therapy were selected from the Erasmus Medical Center Breast Cancer database. Cox proportional hazards models were used to estimate the effect of chemotherapy on recurrence‐free survival (RFS), breast cancer–specific survival (BCSS), and overall survival (OS). Results: A total of 520 patients were selected, of whom 379 were treated with chemotherapy and 141 were not. Patients in the chemotherapy group were younger (51 vs. 61 years old; p <.001), had a higher T status (T3+, 33% vs. 14%; p <.001), and more often had lymph node involvement (80% vs. 49%; p <.001) in comparison to the no‐chemotherapy group. After adjusting for confounders, chemotherapy treatment was not associated with better RFS (hazard ratio [HR], 1.20; 95% confidence interval [CI], 0.63–2.31), BCSS (HR, 1.24; 95% CI, 0.60–2.58), or OS (HR, 0.97; 95% CI, 0.56–1.66). This was also reflected by adjusted Cox survival curves in the chemotherapy versus no‐chemotherapy group for RFS (75% vs. 79%), BCSS (80% vs. 84%), and OS (72% vs. 71%). Conclusions: Chemotherapy is not associated with improved RFS, BCSS, or OS for patients with ER+/HER2− ILC treated with adjuvant endocrine therapy and with an indication for chemotherapy. Chemotherapy is not associated with improved recurrence‐free survival, breast cancer–specific survival, or overall survival for patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative invasive lobular carcinoma treated with endocrine therapy and with an indication for chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.

Author

Boers, Jorianne, Eisses, Bertha, Zwager, Mieke C., van Geel, Jasper J. L., Bensch, Frederike, de Vries, Erik F. J., Hospers, Geke A. P., Glaudemans, Andor W. J. M., Brouwers, Adrienne H., den Dekker, Martijn A. M., Elias, Sjoerd G., Kuip, Evelien J. M., van Herpen, Carla M. L., Jager, Agnes, van der Veldt, Astrid A. M., Oprea-Lager, Daniela E., de Vries, Elisabeth G. E., van der Vegt, Bert, Menke-van der Houven van Oordt, Willemien C., and Schröder, Carolina P.

Subjects
METASTATIC breast cancer, LOBULAR carcinoma, EPIDERMAL growth factor receptors, METASTASIS, HISTOPATHOLOGY, POSITRON emission tomography
Abstract

Background: In metastatic breast cancer (MBC), [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [18F]FDG uptake in corresponding metastases. Patients and Methods: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [18F]FDG uptake was expressed as maximum standardized uptake value (SUVmax) and results were expressed as geometric means. Results: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥ 20% were correlated with higher [18F]FDG uptake (estimated geometric mean SUVmax 10.0 and 8.8, respectively; p = 0.0064 and p = 0.014). [18F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUVmax 6.8 and 10.0, respectively; p = 0.0058). Although [18F]FDG uptake was lower in invasive lobular carcinoma (n = 31) than invasive carcinoma NST (n = 146) (estimated geometric mean SUVmax 5.8 versus 7.8; p = 0.014), the metastasis detection rate was similar. Conclusions: [18F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [18F]FDG uptake, [18F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2 -Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.

Author

Meijer, Titia G., Martens, John W. M., Prager-van der Smissen, Wendy J. C., Verkaik, Nicole S., Beaufort, Corine M., van Herk, Stanley, Robert-Finestra, Teresa, Hoogenboezem, Remco M., Ruigrok-Ritstier, Kirsten, Paul, Maarten W., Gribnau, Joost, Bindels, Eric M. J., Kanaar, Roland, Jager, Agnes, van Gent, Dik C., and Hollestelle, Antoinette

Subjects
OVARIAN tumors, GENETIC mutation, HOMOGRAFTS, SEQUENCE analysis, BRCA genes, FUNCTIONAL status, EARLY detection of cancer, CELLS, GENE expression profiling, DESCRIPTIVE statistics, METHYLATION, RESEARCH funding, CELL lines, BREAST tumors
Abstract

Simple Summary: Cancer cells from patients who carry a disease-causing BRCA1 or BRCA2 mutation are incapable of repairing double-strand DNA breaks via the homologous recombination (HR) repair pathway. As a consequence, these patients respond to platinum-based chemotherapy and Poly-[ADP-Ribose]-Polymerase inhibitors (PARPi). However, using a functional read-out for HR, we show that not all HR-deficient cell lines carry a BRCA1/2 mutation. Moreover, the majority of BRCA1/2-mutant cell lines are HR proficient, highlighting the importance of measuring the functional HR status. For almost all of the BRCA1/2-mutant HR proficient cell lines, we could explain the discrepant HR status. The observed reversion mechanisms predominantly acted on restoring the BRCA1 or BRCA2 mutation directly. Taken together, our results indicate that only determining BRCA1/2 mutation status may not suffice for selecting patients for platinum-based chemotherapy or PARPi. Moreover, for experimental approaches cell line functionality of HR should be assessed beforehand. Tumors with a pathogenic BRCA1/2 mutation are homologous recombination (HR)-deficient (HRD) and consequently sensitive to platinum-based chemotherapy and Poly-[ADP-Ribose]-Polymerase inhibitors (PARPi). We hypothesized that functional HR status better reflects real-time HR status than BRCA1/2 mutation status. Therefore, we determined the functional HR status of 53 breast cancer (BC) and 38 ovarian cancer (OC) cell lines by measuring the formation of RAD51 foci after irradiation. Discrepancies between functional HR and BRCA1/2 mutation status were investigated using exome sequencing, methylation and gene expression data from 50 HR-related genes. A pathogenic BRCA1/2 mutation was found in 10/53 (18.9%) of BC and 7/38 (18.4%) of OC cell lines. Among BRCA1/2-mutant cell lines, 14/17 (82.4%) were HR-proficient (HRP), while 1/74 (1.4%) wild-type cell lines was HRD. For most (80%) cell lines, we explained the discrepancy between functional HR and BRCA1/2 mutation status. Importantly, 12/14 (85.7%) BRCA1/2-mutant HRP cell lines were explained by mechanisms directly acting on BRCA1/2. Finally, functional HR status was strongly associated with COSMIC single base substitution signature 3, but not BRCA1/2 mutation status. Thus, the majority of BRCA1/2-mutant cell lines do not represent a suitable model for HRD. Moreover, exclusively determining BRCA1/2 mutation status may not suffice for platinum-based chemotherapy or PARPi patient selection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Reduction in potentially inappropriate end-of-life hospital care for cancer patients during the COVID-19 pandemic: A retrospective population-based study.

Author

Slotman, Ellis, Fransen, Heidi P, van Laarhoven, Hanneke WM, van den Beuken-van Everdingen, Marieke HJ, Tjan-Heijnen, Vivianne CG, Huijben, Auke MT, Jager, Agnes, van Zuylen, Lia, Kuip, Evelien JM, van der Linden, Yvette M, Raijmakers, Natasja JH, and Siesling, Sabine

Subjects
HOSPITALS, INTENSIVE care units, CONFIDENCE intervals, TERMINAL care, RETROSPECTIVE studies, PATIENTS, REGRESSION analysis, MEDICAL errors, CANCER patients, HOSPITAL admission & discharge, HOSPITAL mortality, HOSPITAL care, DESCRIPTIVE statistics, CHI-squared test, RESEARCH funding, ODDS ratio, LOGISTIC regression analysis, DATA analysis software, PATIENT safety, PALLIATIVE treatment, COVID-19 pandemic, LONGITUDINAL method
Abstract

Background: The COVID-19 pandemic impacted cancer diagnosis and treatment. However, little is known about end-of-life cancer care during the pandemic. Aim: To investigate potentially inappropriate end-of-life hospital care for cancer patients before and during the COVID-19 pandemic. Design: Retrospective population-based cohort study using data from the Netherlands Cancer Registry and the Dutch National Hospital Care Registration. Potentially inappropriate care in the last month of life (chemotherapy administration, >1 emergency room contact, >1 hospitalization, hospitalization >14 days, intensive care unit admission or hospital death) was compared between four COVID-19 periods and corresponding periods in 2018/2019. Participants: A total of 112,919 cancer patients (⩾18 years) who died between January 2018 and May 2021 were included. Results: Fewer patients received potentially inappropriate end-of-life care during the COVID-19 pandemic compared to previous years, especially during the first COVID-19 peak (22.4% vs 26.0%). Regression analysis showed lower odds of potentially inappropriate end-of-life care during all COVID-19 periods (between OR 0.81; 95% CI 0.74–0.88 and OR 0.92; 95% CI 0.87–0.97) after adjustment for age, sex and cancer type. For the individual indicators, fewer patients experienced multiple or long hospitalizations, intensive care unit admission or hospital death during the pandemic. Conclusions: Cancer patients received less potentially inappropriate end-of-life care during the COVID-19 pandemic. Because several factors may have contributed, it is unclear whether this reflects better quality care. However, these findings raise important questions about what pandemic-induced changes in care practices can help provide appropriate end-of-life care for future patients in the context of increasing patient numbers and limited resources. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling

Author

Angus, Lindsay, primary, Smid, Marcel, additional, Wilting, Saskia M., additional, Bos, Manouk K., additional, Steeghs, Neeltje, additional, Konings, Inge R. H. M., additional, Tjan-Heijnen, Vivianne C. G., additional, van Riel, Johanna M. G. H., additional, van de Wouw, Agnes J., additional, Consortium, CPCT, additional, Cuppen, Edwin, additional, Lolkema, Martijn P., additional, Jager, Agnes, additional, Sleijfer, Stefan, additional, and Martens, John W. M., additional

Published
2023
Full Text
View/download PDF

47. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer

Author

Simons, Janine M., van Nijnatten, Thiemo J. A., van der Pol, Carmen C., van Diest, Paul J., Jager, Agnes, van Klaveren, David, Kam, Boen L. R., Lobbes, Marc B., de Boer, Maaike, Verhoef, Cees, Sars, Paul R. A., Heijmans, Harald J., van Haaren, Els R. M., Vles, Wouter J., Contant, Caroline M. E., Menke-Pluijmers, Marian B. E., Smit, Leonie H. M., Kelder, Wendy, Boskamp, Marike, Koppert, Linetta B., Luiten, Ernest J. T., Smidt, Marjolein L., RS: GROW - R2 - Basic and Translational Cancer Biology, Surgery, MUMC+: DA BV AIOS Radiologie (9), Beeldvorming, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), MUMC+: MA Heelkunde (9), Radiotherapy, Medical Oncology, Public Health, and Radiology & Nuclear Medicine

Subjects
Sentinel Lymph Node Biopsy, Breast Neoplasms, Middle Aged, Neoadjuvant Therapy, Iodine Radioisotopes, SDG 3 - Good Health and Well-being, Lymphatic Metastasis, Axilla, Humans, Lymph Node Excision, Surgery, Female, Prospective Studies, Thyroid Neoplasms, Lymph Nodes, Sentinel Lymph Node, Iodine
Abstract

ImportanceSeveral less-invasive staging procedures have been proposed to replace axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) in patients with initially clinically node-positive (cN+) breast cancer, but these procedures may fail to detect residual disease. Owing to the lack of high-level evidence, it is not yet clear which procedure is most optimal to replace ALND.ObjectiveTo determine the diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy (RISAS), a targeted axillary dissection procedure.Design, Setting, and ParticipantsThis was a prospective, multicenter, noninferiority, diagnostic accuracy trial conducted from March 1, 2017, to December 31, 2019. Patients were included within 14 institutions (general, teaching, and academic) throughout the Netherlands. Patients with breast cancer clinical tumor categories 1 through 4 (cT1-4; tumor diameter 5 cm or extension to the chest wall or skin) and pathologically proven positive axillary lymph nodes (ie, clinical node categories cN1, metastases to movable ipsilateral level I and/or level II axillary nodes; cN2, metastases to fixed or matted ipsilateral level I and/or level II axillary nodes; cN3b, metastases to ipsilateral level I and/or level II axillary nodes with metastases to internal mammary nodes) who were treated with NAC were eligible for inclusion. Data were analyzed from July 2020 to December 2021.InterventionPre-NAC, the marking of a pathologically confirmed positive axillary lymph node with radioactive iodine seed (MARI) procedure, was performed and after NAC, sentinel lymph node biopsy (SLNB) combined with excision of the marked lymph node (ie, RISAS procedure) was performed, followed by ALND.Main Outcomes and MeasuresThe identification rate, false-negative rate (FNR), and negative predictive value (NPV) were calculated for all 3 procedures: RISAS, SLNB, and MARI. The noninferiority margin of the observed FNR was 6.25% for the RISAS procedure.ResultsA total of 212 patients (median [range] age, 52 [22-77] years) who had cN+ breast cancer underwent the RISAS procedure and ALND. The identification rate of the RISAS procedure was 98.2% (223 of 227). The identification rates of SLNB and MARI were 86.4% (197 of 228) and 94.1% (224 of 238), respectively. FNR of the RISAS procedure was 3.5% (5 of 144; 90% CI, 1.38-7.16), and NPV was 92.8% (64 of 69; 90% CI, 85.37-97.10), compared with an FNR of 17.9% (22 of 123; 90% CI, 12.4%-24.5%) and NPV of 72.8% (59 of 81; 90% CI, 63.5%-80.8%) for SLNB and an FNR of 7.0% (10 of 143; 90% CI, 3.8%-11.6%) and NPV of 86.3% (63 of 73; 90% CI, 77.9%-92.4%) for the MARI procedure. In a subgroup of 174 patients in whom SLNB and the MARI procedure were successful and ALND was performed, FNR of the RISAS procedure was 2.5% (3 of 118; 90% CI, 0.7%-6.4%), compared with 18.6% (22 of 118; 90% CI, 13.0%-25.5%) for SLNB (P P = .03).Conclusions and RelevanceResults of this diagnostic study suggest that the RISAS procedure was the most feasible and accurate less-invasive procedure for axillary staging after NAC in patients with cN+ breast cancer.

Published
2023

48. Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer

Author

van Geel, Jasper J L, Boers, Jorianne, Elias, Sjoerd G, Glaudemans, Andor W J M, de Vries, Erik F J, Hospers, Geke A P, van Kruchten, Michel, Kuip, Evelien J M, Jager, Agnes, Menke-van der Houven van Oordt, Willemien C, van der Vegt, Bert, de Vries, Elisabeth G E, Schröder, Carolina P, Translational Immunology Groningen (TRIGR), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Molecular Neuroscience and Ageing Research (MOLAR), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Medical Oncology, Internal medicine, and CCA - Imaging and biomarkers

Subjects
Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Cancer Research, SDG 3 - Good Health and Well-being, Oncology
Abstract

PURPOSE Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[18F]fluoro-17β-estradiol positron emission tomography ([18F]FES-PET) is increasingly used for this purpose. To establish the clinical validity of the [18F]FES-PET, we studied the diagnostic accuracy of qualitative and quantitative [18F]FES-PET assessment to predict ER expression by immunohistochemistry in a metastasis. METHODS In a prospective multicenter trial, 200 patients with newly diagnosed MBC underwent extensive workup including molecular imaging. For this subanalysis, ER expression in the biopsied metastasis was related to qualitative whole-body [18F]FES-PET evaluation and quantitative [18F]FES uptake in the corresponding metastasis. A review and meta-analysis regarding [18F]FES-PET diagnostic performance were performed. RESULTS Whole-body [18F]FES-PET assessment predicted ER expression in the biopsied metastasis with good accuracy: a sensitivity of 95% (95% CI, 89 to 97), a specificity of 80% (66 to 89), a positive predictive value (PPV) of 93% (87 to 96), and a negative predictive value (NPV) of 85% (72 to 92) in 181 of 200 evaluable patients. Quantitative [18F]FES uptake predicted ER immunohistochemistry in the corresponding metastasis with a sensitivity/specificity of 91%/69% and a PPV/NPV of 90%/71% in 156 of 200 evaluable patients. For bone metastases, PPV/NPV was 92%/81%. Meta-analysis with addition of our data has increased diagnostic performance and narrowed the 95% CIs compared with previous studies with a sensitivity/specificity of both 86% (81 to 90 and 73 to 93, respectively). CONCLUSION In this largest prospective series so far, we established the clinical validity of [18F]FES-PET to determine tumor ER status in MBC. In view of the high diagnostic accuracy of qualitatively assessed whole-body [18F]FES-PET, this noninvasive imaging modality can be considered a valid alternative to a biopsy of a metastasis to determine ER status in newly MBC (ClinicalTrials.gov identifier: NCT01957332 ).

Published
2022

49. Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels

Author

Jongbloed, Elisabeth M., primary, Jansen, Maurice P.H.M., additional, de Weerd, Vanja, additional, Helmijr, Jean A., additional, Beaufort, Corine M., additional, Reinders, Marcel J. T., additional, Marion, Ronald van, additional, IJcken, Wilfred F. J. van, additional, Sonke, Gabe S., additional, Konings, Inge R. H. M., additional, Jager, Agnes, additional, Martens, John W.M., additional, Wilting, Saskia M., additional, and Makrodimitris, Stavros, additional

Published
2023
Full Text
View/download PDF

50. Supplemental legend from Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects

Author

Meijer, Titia G., primary, Verkaik, Nicole S., primary, Sieuwerts, Anieta M., primary, van Riet, Job, primary, Naipal, Kishan A.T., primary, van Deurzen, Carolien H.M., primary, den Bakker, Michael A., primary, Sleddens, Hein F.B.M., primary, Dubbink, Hendrikus-Jan, primary, den Toom, T. Dorine, primary, Dinjens, Winand N.M., primary, Lips, Esther, primary, Nederlof, Petra M., primary, Smid, Marcel, primary, van de Werken, Harmen J.G., primary, Kanaar, Roland, primary, Martens, John W.M., primary, Jager, Agnes, primary, and van Gent, Dik C., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results